The acquisitions in Latin America are part of Netherlands-based Synthon’s emerging market strategy, which is also looking at opportunities in Eastern Europe and Asia Pacific.
Synthon believes there are benefits in acquiring companies which have a strong reputation in their home territory. This provides Synthon with an established presence in the country which can be enhanced by integrating the acquired business.
Nafar is a developer, manufacturer and distributor of generic drugs to the Mexican market. Its capabilities include the production and marketing of soft-gel formulations in Mexico.